Articles tagged "Immunosuppression"

2017 American Transplant Congress
The Associations Between Body Mass Index and Kidney Transplant Outcomes Are Mediated by Weight-Adjusted Immunosuppression Dosing.
K. Flabouris,^1,2 S. Chadban,^1,3,4 M. Ladhani,^1,3,5 M. Cervelli,⁶ P. Clayton.^1,2,6
¹Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, Adelaide, Australia; ²School of Medicine, University of Adelaide, Adelaide, Australia; ³Sydney Medical School, University of Sydney, Sydney, Australia; ⁴Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ⁵Department of Renal Medicine, Lyell McEwin Hospital, Adelaide, Australia; ⁶Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia
Purpose: High body mass index (BMI) is associated with acute rejection after kidney transplantation. We hypothesised that weight-adjusted immunosuppression dosing is a contributing factor. We…
2017 American Transplant Congress
Rituximab Desensitization (DES) and Alemtuzumab Induction Significantly Reduced EBV Viremia and Post-Transplant Lymphoproliferative Disorder (PTLD) in HLA-Sensitized (HS) Kidney Transplant Patients.
B.-H. Shin,¹ S. Ge,¹ J. Mirocha,² D. Thomas,¹ E. Rodriguez,¹ C. Chao,¹ O. Galera,¹ A. Vo,¹ J. Choi,¹ A. Peng,¹ J. Kahwaji,¹ S. Jordan,¹ M. Toyoda.¹
¹Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Biostatistics Core, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA
Background: PTLD is a serious complication in KTx pts and is usually associated with EBV infection. Recent studies showed that rituximab treatment prior to Tx…
2017 American Transplant Congress
Tacrolimus and Mycophenolic Acid Have a Limited Inhibitory Effect on Monocyte Signaling Pathway Phosphorylation, Function and Differentiation.
N. Kannegieter,¹ D. Hesselink,¹ M. Dieterich,¹ R. Kraaijeveld,¹ A. Rowshani,¹ P. Leenen,² C. Baan.¹
¹Internal Medicine, Erasmus MC, Rotterdam, Netherlands; ²Immunology, Erasmus MC, Rotterdam, Netherlands
Introduction Monocytes and macrophages play key roles in cellular and humoral rejection after solid organ transplantation, but little is known about the effects of the…
2017 American Transplant Congress
The Inhibitory Effect of Plasma on T Cell Activation: Possible Role of Plasma Exchange in Anti Rejection Therapy.
A. Assounga,^1,2 S. Omarjee.¹
¹Dept Nephrology, University of KwaZulu-Natal, Durban, South Africa; ²Inkosi Albert Luthuli Central Hospital, Durban, South Africa
Reduction of lymphocyte proliferation by human plasma has been previously reported. Reduced activation of lymphocytes of patients on immunosuppressive drugs is well documented.Aim: To compare…
2017 American Transplant Congress
Clinical Outcomes of Kidney Transplant Recipients by Steroid Early Withdraw Protocol with Basiliximab Induction.
Y. Takada, K. Hotta, D. Iwami, H. Higuchi, T. Hirose, H. Sasaki, N. Shinohara.
Urology, Hokkaido University Hospital, Sapporo, Japan
[Purpose] Several steroid early withdrawal protocols (SEWD) have been attempted in recent decades to avoid steroid related adverse effects among kidney transplant recipients. However, there…
2017 American Transplant Congress
Time to First Therapeutic Tacrolimus Level: What Impact Does It Have After Heart Transplantation?
O. Witkowsky, J. Teuteberg, C. Sciortino, M. Shullo.
University of Pittsburgh Medical Center, Pittsburgh, PA
Purpose: Appropriate time to therapeutic immunosuppression levels is not well defined. The purpose of this study is to investigate outcomes related to time to therapeutic…
2017 American Transplant Congress
Generation of Potent Monocytic Myeloid-Derived Suppressor Cells from Rhesus Macaque Bone Marrow.
A. Thomson, A. Zahorchak, A. Perez-Gutierrez, M. Ezzelarab.
Surgery (Transplant), University of Pittsburgh, Pittsburgh, PA
Background: Myeloid-derived suppressor cells (MDSC) have shown promise in inhibiting allograft rejection and in promoting transplant tolerance in rodent models. We recently reported that monocytic…
2017 American Transplant Congress
One Year Outcomes of Low-Dose vs Very Low-Dose Extended-Release Tacrolimus/Mycophenolate mofetil in De Novo Kidney Transplantation: A Multi-Center Randomized Controlled Trial.
Y. Hidaka,¹ S. Yamanaga,¹ M. Toyoda,¹ S. Narumi,² Y. Watarai,² T. Kobayashi.³
¹Kidney Center, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; ²Transplant Surgery, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Aichi, Japan; ³Kidney Transplantation, Aichi Medical University, Nagoya, Aichi, Japan
Purpose: Once-daily tacrolimus extended-release formulation (TACER) has now been widely accepted in kidney transplant field. However, the optimal dosage for TACER is still not known.Patients…
2017 American Transplant Congress
Risks Associated with Recombinant IL2 Therapy in Renal Transplantation.
M. McGrath, S. Tripathi, A. Chandraker.
Brigham and Women's Hospital, Boston
Regulatory T cells are critical to allograft survival. We report a pilot study of safety and tolerability of low dose recombinant IL2 (rIL2), 1x106 units/m2/day…
2017 American Transplant Congress
National Variation in Liver Transplant Immunosuppression in the U.S..
M. Nazzal,¹ R. Ouseph,¹ M. Schnitzler,¹ Z. Zhang,¹ D. Axelrod,² D. Segev,³ A. Naik,⁴ H. Randall,¹ D. Brennan,⁵ B. Kasiske,⁶ G. Hess,⁷ T. Alhamad,⁵ K. Lentine.¹
¹St Louis Univ, St Louis; ²E Carolina Univ, Greenville; ³Johns Hopkins, Baltimore; ⁴U Michigan, Ann Arbor; ⁵Washington Univ, St Louis; ⁶SRTR, Minneapolis; ⁷Symphony Health, Philadelphia
Variation in immunosuppression (ISx) for liver transplant (LTx) across US programs has not been described. We examined a novel database integrating national registry and pharmacy…